Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy  by Tzeng, Ching-Wei D. et al.
ORIGINAL ARTICLE
Yield of clinical and radiographic surveillance in patients with
resected pancreatic adenocarcinoma following multimodal therapy
Ching-Wei D. Tzeng1, Jason B. Fleming1, Jeffrey E. Lee1, Xuemei Wang2, Peter W. T. Pisters1, Jean-Nicolas Vauthey1,
Gauri Varadhachary3, Robert A. Wolff 3 & Matthew H. G. Katz1
Departments of 1Surgical Oncology, 2Biostatistics, and 3Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston,
TX, USA
Abstracthpb_445 365..372
Background: Following potentially curative resection at this centre, patients with pancreatic adenocar-
cinoma (PAC) are routinely enrolled in a programme of clinical and radiographic surveillance. This study
sought to evaluate its diagnostic yield.
Methods: All patients who underwent pancreaticoduodenectomy for PAC at this institution during
1998–2008 were identified. Patients with asymptomatic recurrence were compared with those with
symptomatic recurrence. Factors associated with survival following the detection of recurrence were
compared.
Results: A total of 216 of 327 (66.1%) resected patients developed recurrence. Asymptomatic recur-
rence was detected in 118 (54.6%) patients. Symptomatic recurrence was associated with multifocal
disease or carcinomatosis, poor performance status and less frequent subsequent therapy. Median time
to recurrence did not differ between groups, but survival after detection was shorter in symptomatic
patients (5.1 months vs. 13.0 months; P < 0.001). Treatment was administered more frequently to asymp-
tomatic patients (91.2% vs. 61.4%; P < 0.001). At recurrence, a preserved performance status score of
1, further therapy, low CA 19-9, and an isolated site of recurrence were independently associated with
longer post-recurrence survival (P < 0.001).
Conclusions: Overall, 54.6% of cases of recurrent PAC were detected prior to the onset of symptoms
using a standardized clinical and radiographic surveillance strategy. Although this retrospective analysis
limits definitive conclusions associating this strategy with survival, these results suggest the need for
further studies of postoperative surveillance.
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Introduction
Patients with many solid cancers who develop recurrence follow-
ing potentially curative resection can often be treated with che-
motherapy, radiation or reoperation when their disease burden is
limited. There is, thus, a sound rationale for the use of routine
surveillance programmes designed to identify low-volume, recur-
rent disease prior to the onset of symptoms. Advantages associ-
ated with the surveillance of patients with high-risk colorectal
cancer have been described.1–3 Routine surveillance has also been
advocated for patients with breast cancer,4 gastric cancer5 and
melanoma.6
Series of longterm survivors published within the last decade
suggest that up to 27% of patients with localized pancreatic
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adenocarcinoma (PAC) who complete multimodal therapy
survive for >5 years.7 Nonetheless, most patients who receive
potentially curative therapy for PAC develop recurrence. For such
patients, systemic chemotherapy is not curative. Similarly, reop-
eration following pancreatic resection is typically futile.8–10
Probably in response to a resulting therapeutic nihilism, few data
have been published on the incidence, pattern and treatment of
recurrent PAC,11 and no analysis has been performed of
outcomes associated with surveillance or treatment of recurrence
following multimodal therapy. Essentially, no data exist to help
guide postoperative follow-up.
The National Comprehensive Cancer Network (NCCN) rec-
ommends the routine surveillance of patients who have under-
gone resection for PAC with a physical examination and clinical
assessment for the presence of symptoms every 6 months for
2 years, but does not advocate radiographic imaging because data
demonstrating its efficacy are lacking. The NCCN further recom-
mends that recurrence be treated with chemotherapy and/or
chemoradiation, preferably as part of a clinical trial.12 However,
the frequency with which recurrent PAC is detected when patients
are eligible for treatment using this strategy is unknown.
It has long been hypothesized that a comprehensive surveil-
lance strategy that includes both clinical assessment and radio-
graphic evaluation might identify recurrent PAC when it is most
amenable to further treatment. At this institution, patients are
enrolled into an intensive surveillance programme following
resection, and are liberally treated for recurrence upon detection.
Through an analysis of patients curatively treated for localized
PAC, this retrospective study aims to describe patterns and timing
of recurrent PAC, to determine the rates of asymptomatic and
symptomatic recurrence detected with this surveillance strategy,
to characterize patients’ performance status and clinical charac-
teristics at the time of recurrence, and to identify factors associ-
ated with survival following recurrence.
Materials and methods
Patients and staging
The centre’s prospectively maintained pancreatic database was
retrospectively queried for patients diagnosed with potentially
resectable or borderline resectable adenocarcinoma of the pancre-
atic head or uncinate process, who underwent pancreati-
coduodenectomy during 1998–2008.13 Staging was established
using multidetector, contrast-enhanced computed tomography
(CT) and was confirmed when necessary by multidisciplinary
review. The staging criteria have been previously reported.14
Primary treatment
Patients with localized PAC often received chemotherapy and/or
chemoradiation, either on or off protocol, prior to resection.14–16
Most patients received external beam radiation (typically to
30.0 Gray or 50.4 Gray) with concurrent gemcitabine,
5-fluorouracil or capecitabine. Gemcitabine-based systemic che-
motherapy was delivered prior to chemoradiation in selected
patients. Patients who underwent surgery first routinely received
postoperative therapy.17 Pancreaticoduodenectomy was per-
formed in a standard fashion.18
Follow-up and surveillance
Following completion of all therapy, patients were scheduled for
re-evaluation every 3–4 months with a physical examination,
chest radiograph and abdominal CT scan. Serum carbohydrate
antigen 19-9 (CA 19-9) was typically, but not always, assayed.
Patients without evidence of disease after 2 years from diagnosis
were evaluated every 6 months to year 5, when evaluations were
reduced to annual intervals. Magnetic resonance imaging was only
used when patients were unable to undergo CT, and positron
emission tomography scans were rarely employed.
Recurrence was considered symptomatic when it was detected
concurrently with a significant patient-initiated complaint that
was new or had increased in either severity or frequency during
the prior surveillance interval, or was detected during physical
examination. Symptomatic recurrences were diagnosed either at
scheduled visits or at accelerated, unscheduled visits. Asymptom-
atic recurrences were defined as those discovered by routine
imaging at scheduled visits in the absence of new complaints or
physical findings. Performance status at recurrence was reported
using the Eastern Cooperative Oncology Group (ECOG) score.19
Recurrence was classified as local, regional or distant.20 The
development of a new, low-density mass in the region of the
resected pancreas or in the mesenteric root was considered local.
Abdominal ascites and enlarging regional lymph nodes were con-
sidered regional. A new low-density mass in the liver, in the lung
or outside the abdomen was considered distant. When radio-
graphic findings were consistent with cancer, biopsy was rarely
performed. Only the first site(s) of recurrence was recorded for
this study. Following recurrence, treatment was initiated at the
discretion of the multidisciplinary group. Gemcitabine-based sys-
temic chemotherapy was typically employed; chemoradiation and
re-resection were rarely used.
Statistical analysis
Chi-squared and Fisher’s exact tests were used for categorical
variables. Wilcoxon rank-sum test was used to compare continu-
ous variables. To reveal any potential difference in actual patterns
of surveillance between symptomatic and asymptomatic patients,
the median interval between surveillance CT scans was calculated
for each patient from postoperative day 30 (to exclude acute post-
operative scans) to the date of recurrence by dividing this dura-
tion with the number of abdominal CT scans actually obtained in
that period. Time to recurrence (TTR) in patients affected by
recurrence was defined as the interval between tissue diagnosis
and detection of recurrence. Disease-free survival (DFS) was mea-
sured from diagnosis to whichever occurred first of the date of
recurrence or the date of the last follow-up. Overall survival (OS)
was defined as the interval between diagnosis and the date of
death from any cause or last follow-up, whichever occurred first.
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Post-recurrence overall survival (PROS) was defined as the inter-
val between recurrence and the date of death from any cause or
last follow-up, whichever occurred first. Overall survival and
PROS were estimated using the Kaplan–Meier method. The log-
rank test was used to compare OS and PROS among various
subgroups. The variable ‘symptom at recurrence’ was treated as a
time-varying covariate when assessing its effect on OS because
symptoms were recorded at disease recurrence rather than disease
diagnosis. It serves as a baseline covariate when assessing its effect
on PROS. ‘Symptom at recurrence’ was considered as a time-
dependent covariate when Cox proportional hazards models were
used to analyse associations between PROS and clinical character-
istics. Univariate factors with P < 0.10 were included in the mul-
tivariate model. Statistical analyses were performed using sas
Version 9.2 (SAS Institute, Inc., Cary, NC, USA) and s-plus
Version 8 (TIBCO Software, Inc., Somerville, MA, USA).
Results
Overall survival in 327 patients
A total of 356 patients who underwent pancreaticoduodenectomy
for PAC during 1998–2008 fulfilled the study inclusion criteria.
Complete follow-up data were available for 327 (91.9%) patients.
The median follow-up for all patients was 30.5 months (range:
3.3–147.8 months). In patients without recurrence, median
follow-up was 46.1 months (range: 3.3–147.8 months). Neoadju-
vant therapy was administered to 254 of 327 (77.7%) patients. Of
the 73 patients who did not receive preoperative therapy, 50
(68.5%) patients were given postoperative therapy. The median
OS and DFS in all 327 patients were 33.4 months [95% confidence
interval (CI) 30.5–38.2] and 19.1 months (95% CI 16.8–22.7),
respectively.
Timing and pattern of recurrence
Recurrent PAC was documented in 216 of 327 (66.1%) patients at
last follow-up. The first site of recurrence was identified in the
pancreas in 32 of 327 (9.8%) patients, as regional disease in 31 of
327 (9.5%) patients (peritoneum, n = 27; regional lymph nodes,
n = 4), and at distant sites in 108 of 327 (33.0%) patients (liver,
n = 58; lung, n = 35; other, n = 3; multiple distant sites, n = 12).
In 45 of 327 (13.8%) patients, recurrence was documented
simultaneously in at least two site groups.
The median TTR in patients with recurrence was 13.3 months
(95% CI 11.8–14.7) from diagnosis. The first recurrence was
documented within 2 years of diagnosis in 174 of 216 (80.6%)
patients with recurrence (and 53.2% of all 327 patients) (Fig. 1).
Recurrence was identified in 26.9% (88/327), 37.7% (86/228) and
17.4% (23/132) of patients at risk in each of the first 3 years
following diagnosis. Thereafter, only 3.0–10.5% of patients at risk
were diagnosed with recurrent disease annually to year 7.
Detection and characteristics of recurrence
Ninety-eight of 216 (45.4%) recurrences were diagnosed in the
presence of concurrent symptoms. Abdominal or back pain was
Figure 1 Recurrence was detected in the absence of symptoms in approximately half of all patients who experienced recurrence each year
to year 7. Detection yield was highest in the first 2 years of surveillance and fell sharply thereafter
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reported by 76 of 98 (77.6%) symptomatic patients. Asymptom-
atic recurrence was diagnosed in 118 of 216 (54.6%) patients.
Annual percentages of symptomatic recurrences ranged from
36.0% to 52.3%. There was no significant difference in the median
frequency of surveillance CT scans between symptomatic and
asymptomatic patients with recurrence (P > 0.325) (Table 1).
Initial demographics, treatment variables, perioperative factors
and pathologic characteristics associated with the primary
tumour did not differ between symptomatic and asymptomatic
patients (Table 1). However, patterns of recurrence (P = 0.010)
and distributions of ECOG scores (P = 0.001) differed between
symptomatic and asymptomatic patients. The median CA 19-9 in
symptomatic patients also trended higher than in asymptomatic
patients (P = 0.050).
Median TTR did not differ between patients with symptomatic
and asymptomatic recurrence [12.3 months (95% CI 11.6–13.0)
vs. 14.5 months (95% CI 12.3–16.6); P = 0.380]. However, symp-
tomatic patients had a shorter median PROS than patients
without symptoms [5.1 months (95% CI 3.4–6.8) vs. 13.0 months
(95% CI 10.8–15.1); P < 0.001]. Thus, the median OS of symp-
tomatic patients [18.0 months (95% CI 15.9–24.7)] was shorter
than in asymptomatic patients [29.6 months (95% CI 25.9–34.0)]
(P = 0.003) (Fig. 2).
Treatment for recurrence
Further therapy was administered in 157 of 216 (72.7%) patients
with recurrence. Treatment was administered more frequently in
asymptomatic than in symptomatic patients (91.2% vs. 61.4%;
P < 0.001). Median PROS was longer in treated patients than
in untreated patients [11.8 months (95% CI 9.8–13.7) vs.
2.6 months (95% CI 2.6–3.2); P < 0.001].
Among 158 patients with preserved performance status (ECOG
score  1) at recurrence, 136 (86.1%) received subsequent
therapy. The reasons why the remaining 22 patients did not
receive further treatment were patient choice (n = 11) and physi-
cian recommendation (n = 11). The median PROS of patients
with ECOG scores of  1 treated following recurrence was longer
Table 1 Tumour and patient characteristics in 216 patients who experienced recurrence after potentially curative resection
Categories All patients with
recurrence
Patients without
symptoms
Patients with symptoms P-value
Recurrence, n (%) 216 118 (54.6%) 98 (45.4%)
Primary stage, n (%)
Potentially resectable 191 99 (83.9%) 92 (93.9%) 0.030
Borderline 25 19 (16.1%) 6 (6.1%)
Time interval per CT, months, median (range)
Recurrence at <2 years 3.2 (1.3–10.1) 3.4 (1.3–10.1) 3.1 (1.5–6.4) 0.330
Recurrence at 2–5 years 4.1 (2.9–17.1) 4.1 (2.9–8.5) 3.8 (3.3–17.1) 0.810
Time to recurrence, monthsa
Median (range) 13.3 (1.3–83.8) 14.5 (1.3–83.5) 12.3 (1.6–83.8) 0.380
Recurrence site, n (%)
Local 32 17 (14.4% 15 (15.3%) 0.010
Regional 31 11 (9.3%) 20 (20.4%)
Distant 108 70 (59.3%) 38 (38.8%)
Multiple 45 20 (16.9%) 25 (25.5%)
Performance status at recurrence (ECOG score), n (%)
1 166 116 (99.1%) 50 (51.0%) <0.001
2 49 1 (0.9%) 48 (49.0%)
CA 19-9 at recurrence, n (%)
>40 U/ml 149 80 (69.6%) 69 (75.8%) 0.320
<40 U/ml 57 35 (30.4%) 22 (24.2%)
Median (range), U/ml 181 (1–21 096) 135 (1–21 096) 365 (1–20 934) 0.050
Treatment after recurrence, n (%)
Yes 157 103 (91.2%) 54 (61.4%) <0.001
No 44 10 (8.8%) 34 (38.6%)
aTime to recurrence was measured from the date of tissue diagnosis.
Evaluated and both clinically and statistically not significant: age at recurrence; gender; administration of neoadjuvant therapy prior to initial operation;
estimated blood loss; use of vascular resection; resection margin; nodal status at initial operation; tumour size, and tumour differentiation.
CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate antigen 19-9.
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than that of patients who were untreated [14.1 months (95%
CI 11.5–16.6) vs. 4.2 months (95% CI 0.1–8.8); P < 0.001].
Factors associated with PROS
Four clinical factors independently associated with longer PROS
were identified: isolated recurrence (local or distant recurrence
was better than regional and multiple-site recurrence); preserved
performance status (ECOG scores of 1); lower CA 19-9, and the
administration of therapy for recurrence (Table 2). Further
therapy was also independently associated with longer PROS in a
separate multivariate model of the subgroup of patients with
ECOG scores of  1 at recurrence. Among patients with ECOG
scores of  1 at recurrence, younger age, lower estimated blood
loss at pancreatectomy, lower CA 19-9 level at recurrence, longer
TTR, and isolated (vs. multiple-site) recurrence were indepen-
dently associated with longer PROS (Table 3).
Discussion
For the past two decades, the treatment strategy for localized
adenocarcinoma of the pancreatic head at the study centre has
emphasized objective clinical staging, liberal use of preoperative
chemoradiation, and a uniform approach to the technical aspects
of pancreaticoduodenectomy.7,21 This centre has also enrolled
resected patients into a programme of clinical and radiographic
cancer surveillance. This retrospective analysis of the diagnostic
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Figure 2 (a) Overall survival (P = 0.003) and (b) post-recurrence overall survival (P < 0.001) were both longer in asymptomatic patients
compared with patients in whom recurrence was detected concurrently with symptoms
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yield of the surveillance strategy found that approximately half of
patients with new recurrence each year were detected in the
absence of symptoms. The performance status of these asymp-
tomatic patients was well preserved and 91.2% received further
treatment. By contrast, recurrence detected concurrently with new
symptoms or physical findings was often associated with carcino-
matosis or multifocal disease, depressed performance status that
often prohibited further therapy, and rapid clinical decline. These
results suggest that radiographic surveillance programmes might
identify patients with performance status and tumour biology
Table 2 Factors associated with post-recurrence overall survival (all patients, n = 216)
Clinical characteristic Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Patient traits
Age 1.02 1.01–1.04 0.002
Perioperative factors
Length of stay 1.56 1.07–2.27 0.020
Estimated blood loss 1.3 1.05–1.61 0.020
Factors at recurrence
DFS > 1 year vs.  1 year 1.64 1.22–2.17 <0.001
Symptomatic at recurrence 2.02 1.52–2.68 <0.001 1.16 0.81–1.67 0.410
Recurrence group
Local vs. multiple 0.41 0.25–0.66 <0.001 0.38 0.22–0.64 <0.001
Regional vs. multiple 0.57 0.35–0.92 0.020 0.60 0.36–1.00 0.040
Distant vs. multiple 0.45 0.31–0.64 <0.001 0.46 0.31–0.69 <0.001
ECOG score at recurrence (ECOG 2–4 vs. 0–1) 5.00 3.45–7.14 <0.001 4.01 2.57–6.25 <0.001
CA 19-9 at recurrence 1.22 1.13–1.31 <0.001 1.19 1.10–1.28 <0.001
Treatment at recurrence 0.24 0.17–0.35 <0.001 0.31 0.21–0.47 <0.001
Patient and tumour factors evaluated and insignificant on both univariate and multivariate analysis: gender; clinical stage at initial operation;
neoadjuvant therapy; microscopic margin status; vascular resection; tumour size; tumour differentiation, and lymph node status.
HR, hazard ratio; 95% CI, 95% confidence interval; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate
antigen 19-9.
Table 3 Factors associated with post-recurrence overall survival (patients with ECOG scores  1, n = 166)
Clinical characteristic Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Patient traits
Age 1.02 1.00–1.04 0.020 1.03 1.01–1.05 0.001
Perioperative factors
Estimated blood loss 1.28 1.00–1.65 0.050 1.44 1.09–1.92 0.010
Factors at recurrence
DFS > 1 year vs.  1 year 0.56 0.40–0.78 <0.001 0.45 0.30–0.67 <0.001
Symptomatic 1.37 0.97–1.95 0.080 1.05 0.71–1.55 0.820
Recurrence group
Local vs. multiple 0.39 0.22–0.67 <0.001 0.42 0.22–0.79 0.007
Regional vs. multiple 0.40 0.22–0.71 0.002 0.48 0.26–0.90 0.020
Distant vs. multiple 0.39 0.25–0.60 <0.001 0.40 0.26–0.66 <0.001
CA 19-9 at recurrence 1.21 1.11–1.32 <0.001 1.20 1.09–1.31 <0.001
Treatment at recurrence 0.24 0.20–0.51 <0.001 0.23 0.13–0.38 <0.001
Patient and tumour factors evaluated and insignificant on both univariate and multivariate analysis: gender; clinical stage at initial operation;
neoadjuvant therapy; length of stay at initial operation; microscopic margin status; vascular resection; tumour size; tumour differentiation, and lymph
node status.
ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; 95% CI, 95% confidence interval; DFS, disease-free survival; CA 19-9, carbohydrate
antigen 19-9.
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that are most likely to benefit from subsequent therapy. However,
the limitations and biases of retrospective analyses of surveillance
programmes, like this one, highlight a need for further prospective
study.
A primary objective of this study was to describe the timing and
pattern of recurrent disease detected using an intensive surveil-
lance strategy in patients with resected PAC. The present authors
routinely recommend follow-up every 3–4 months during the
first 2 years, every 6 months in years 3–5, and annually thereafter.
This frequency of surveillance is similar to that recommended by
the NCCN within the first 2 years after resection and is rational
given the timing of recurrence in patients with resected PAC.
Indeed, 80.6% of recurrences in this series occurred within the
first 2 years. After 2 years, the detection of recurrence among
survivors at risk decreased dramatically. Nonetheless, historically
this centre has continued to follow patients beyond 2 years, at
longer intervals, and has used these visits to evaluate patients not
only for recurrence, but also for the nutritional, metabolic and
psychosocial abnormalities that are unique to longterm post-
pancreatectomy survivors. This policy is consistent with recent
data demonstrating that regularly scheduled visits to a physician
are welcomed by cancer patients who have undergone resection.22
However, radiographic surveillance itself may also be a source of
considerable anxiety and fear of recurrence that translates into a
negative effect on quality of life.23 The potential benefits of radio-
graphic surveillance, particularly the longterm benefits, therefore
require additional study.
A second objective of this study was to characterize the
performance status of patients diagnosed with recurrent cancer
using the present strategy. Poor performance status has been
identified as an independent negative prognostic factor in
patients with all stages of PAC treated with chemotherapy,
chemoradiation or surgery.24–26 The reasons for this association
are multifactorial, but include a significant disease burden or
unfavourable tumour biology, which often occur in patients with
poor performance status who are unable to undergo aggressive
therapy. In this series, the presence of new symptoms at recur-
rence was associated with an ECOG score of  2 in 49.0% of
patients. Symptoms were also more common in patients with
carcinomatosis, multiple synchronous sites of recurrence and
higher CA 19-9 levels. These data suggest that the onset of
symptoms may indicate a rapid clinical decline that is already in
progress and that precludes further therapy. This issue is par-
ticularly relevant given the potential role of FOLFIRINOX
(5-fluorouracil, leucovorin, irinotecan, oxaliplatin), a newer
regimen associated with both significant activity and toxicity, in
the treatment of recurrent PAC.27
Although the results of this analysis suggest that the use of
radiographic surveillance might identify patients with a perfor-
mance status that indicates they are suitable for treatment and
may even be associated with a survival benefit, this interpreta-
tion of the present data must be made cautiously and the influ-
ence of bias must be acknowledged. Lead time bias describes the
possibility that the increase in survival duration following detec-
tion by a screening test is an artefact of earlier diagnosis and
does not reflect a true prolongation of life. In the present series,
the TTR of asymptomatic patients was equivalent to that of
symptomatic patients, suggesting that lead time bias was not the
primary reason for improved survival. Furthermore, the absence
of an independent association between symptoms at recurrence
and PROS on multivariate analysis can be explained by the close
correlation between symptoms and performance status, of which
the latter was retained in the final multivariate model. Length
time bias may also have influenced these results. This bias reflects
the possibility that a screening test may detect only patients with
indolent disease and miss patients with more aggressive cancer.
Whether the tumours in asymptomatic patients were more slow-
growing than those in symptomatic patients, and whether the
interval until the onset of symptoms and functional decline
would have been longer in asymptomatic patients had they been
followed until symptoms manifested, are unknown. Because this
was not a prospective trial, it is possible that a disparity in the
actual intensity of follow-up affected the results. However, little
difference in the median time interval between surveillance scans
emerged between patients with asymptomatic and symptomatic
recurrences. Finally, this study is also limited by the absence of
cost-effectiveness data. Given the current economic environment
in which justification for health care expenditures is critical, this
limitation is significant. A rigorous analysis is currently under-
way to address this issue.
Despite these limitations, this analysis has some important
strengths. The foremost of these is the quality of the follow-up
reported in this retrospective study. Indeed, to the authors’ knowl-
edge, this clinical series represents the most comprehensive
follow-up of resected PAC patients with recurrences to be
reported. Thorough clinical data, from diagnosis to death, for all
patients with pancreatic tumours are prospectively logged in a
multidisciplinary database maintained by dedicated personnel.13
Complete follow-up data were available for 91.9% of the 356
patients who fulfilled the present study’s inclusion criteria. This
analysis is therefore subject to minimal selection bias compared
with prior analyses of PAC recurrence in which complete
follow-up data referred to as few as 20% of patients.11,28
In summary, this study found that a regularly scheduled clini-
cal and radiographic surveillance programme detected recur-
rence prior to the onset of symptoms in over half of patients
who underwent curative resection for PAC. The detection yield
was highest in the first 2 years of surveillance and fell sharply
thereafter. If the primary purpose of postoperative surveillance is
to detect recurrence when it is treatable, these data suggest that
routine radiographic surveillance of patients with resected
PAC may be worthwhile, particularly within the first 2 years.
However, further prospective studies are necessary to determine
the precise clinical efficacy of postoperative follow-up and treat-
ment, as well as the optimal timing with regard to resource allo-
cation and cost.
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